Modulating SHP2 and SHP2-related signaling pathways can potentially contribute to bone development and treatment of degenerative diseases, and SHP2 acts as a vital regulator in osteoblast and osteoclast formation [28]. The gene discussed is PTPN11; the disease is neurodegenerative disease.